Date: 2012-04-26
Type of information: Fundraising
Company: Innovacell (Austria)
Investors: Buschier (Switzerland)
Fides (Austria)
HYBAG (Switzerland)
uni venture
Amount: € 8.3 million
Funding type:
Planned used: The new capital will flow directly into the clinical development of Innovacell\'s cell-therapy for the treatment of stress-urinary incontinence ICES13. The multi-centre, randomised Phase III study involving 370 patients is beginning now and will be carried out in several European countries.
Others: Innovacell's shareholders have agreed on a capital expansion of € 8.3 million Euro. This will take effect in two tranches. The main shareholders are the financial investors Buschier, Fides, HYBAG und the private equity firm, uni venture.
Therapeutic area: Regenerative medicine
